Cytomegalovirus blood reactivation in COVID-19 critically ill patients: risk factors and impact on mortality.
COVID-19
Cytomegalovirus reactivation
Mechanical ventilation
Sepsis
Journal
Intensive care medicine
ISSN: 1432-1238
Titre abrégé: Intensive Care Med
Pays: United States
ID NLM: 7704851
Informations de publication
Date de publication:
06 2022
06 2022
Historique:
received:
28
01
2022
accepted:
22
04
2022
pubmed:
19
5
2022
medline:
22
6
2022
entrez:
18
5
2022
Statut:
ppublish
Résumé
Cytomegalovirus (CMV) reactivation in immunocompetent critically ill patients is common and relates to a worsening outcome. In this large observational study, we evaluated the incidence and the risk factors associated with CMV reactivation and its effects on mortality in a large cohort of patients affected by coronavirus disease 2019 (COVID-19) admitted to the intensive care unit (ICU). Consecutive patients with confirmed SARS-CoV-2 infection and acute respiratory distress syndrome admitted to three ICUs from February 2020 to July 2021 were included. The patients were screened at ICU admission and once or twice per week for quantitative CMV-DNAemia in the blood. The risk factors associated with CMV blood reactivation and its association with mortality were estimated by adjusted Cox proportional hazards regression models. CMV blood reactivation was observed in 88 patients (20.4%) of the 431 patients studied. Simplified Acute Physiology Score (SAPS) II score (HR 1031, 95% CI 1010-1053, p = 0.006), platelet count (HR 0.0996, 95% CI 0.993-0.999, p = 0.004), invasive mechanical ventilation (HR 2611, 95% CI 1223-5571, p = 0.013) and secondary bacterial infection (HR 5041; 95% CI 2852-8911, p < 0.0001) during ICU stay were related to CMV reactivation. Hospital mortality was higher in patients with (67.0%) than in patients without (24.5%) CMV reactivation but the adjusted analysis did not confirm this association (HR 1141, 95% CI 0.757-1721, p = 0.528). The severity of illness and the occurrence of secondary bacterial infections were associated with an increased risk of CMV blood reactivation, which, however, does not seem to influence the outcome of COVID-19 ICU patients independently.
Identifiants
pubmed: 35583676
doi: 10.1007/s00134-022-06716-y
pii: 10.1007/s00134-022-06716-y
pmc: PMC9116062
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
706-713Investigateurs
Massimo Girardis
(M)
Alberto Andreotti
(A)
Emanuela Biagioni
(E)
Filippo Bondi
(F)
Stefano Busani
(S)
Giovanni Chierego
(G)
Marzia Scotti
(M)
Lucia Serio
(L)
Annamaria Ghirardini
(A)
Marco Sita
(M)
Stefano De Julis
(S)
Lara Donno
(L)
Lorenzo Dall'Ara
(L)
Fabrizio Di Salvo
(F)
Carlotta Farinelli
(C)
Laura Rinaldi
(L)
Ilaria Cavazzuti
(I)
Andrea Ghidoni
(A)
Antonio Buono
(A)
Elena Ferrari
(E)
Daniela Iseppi
(D)
Anna Maria Ardito
(AM)
Irene Coloretti
(I)
Sophie Venturelli
(S)
Elena Munari
(E)
Martina Tosi
(M)
Erika Roat
(E)
Ilenia Gatto
(I)
Marco Sarti
(M)
Andrea Cossarizza
(A)
Caterina Bellinazzi
(C)
Rebecca Borella
(R)
Sara De Biasi
(S)
Anna De Gaetano
(A)
Lucia Fidanza
(L)
Lara Gibellini
(L)
Anna Iannone
(A)
Domenico Lo Tartaro
(DL)
Marco Mattioli
(M)
Milena Nasi
(M)
Annamaria Paolini
(A)
Marcello Pinti
(M)
Cristina Mussini
(C)
Giovanni Guaraldi
(G)
Marianna Meschiari
(M)
Alessandro Cozzi-Lepri
(A)
Jovana Milic
(J)
Marianna Menozzi
(M)
Erica Franceschini
(E)
Gianluca Cuomo
(G)
Gabriella Orlando
(G)
Vanni Borghi
(V)
Antonella Santoro
(A)
Margherita Di Gaetano
(M)
Cinzia Puzzolante
(C)
Federica Carli
(F)
Andrea Bedini
(A)
Luca Corradi
(L)
Enrico Clini
(E)
Roberto Tonelli
(R)
Riccardo Fantini
(R)
Ivana Castaniere
(I)
Luca Tabbì
(L)
Giulia Bruzzi
(G)
Chiara Nani
(C)
Fabiana Trentacosti
(F)
Pierluigi Donatelli
(P)
Maria Rosaria Pellegrino
(MR)
Linda Manicardi
(L)
Antonio Moretti
(A)
Morgana Vermi
(M)
Caterina Cerbone
(C)
Monica Pecorari
(M)
William Gennari
(W)
Antonella Grottola
(A)
Giulia Fregni Serpini
(GF)
Informations de copyright
© 2022. Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Limaye AP, Kirby KA, Rubenfeld GD et al (2008) Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 300:413–422. https://doi.org/10.1001/jama.300.4.413
doi: 10.1001/jama.300.4.413
pubmed: 18647984
pmcid: 2774501
Imlay H, Dasgupta S, Boeckh M et al (2021) Risk factors for cytomegalovirus reactivation and association with outcomes in critically ill adults with sepsis: a pooled analysis of prospective studies. J Infect Dis 223:2108–2112. https://doi.org/10.1093/infdis/jiaa697
doi: 10.1093/infdis/jiaa697
pubmed: 33159200
Hraiech S, Bonnardel E, Guervilly C et al (2019) Herpes simplex virus and Cytomegalovirus reactivation among severe ARDS patients under veno-venous ECMO. Ann Intensive Care 9:142. https://doi.org/10.1186/s13613-019-0616-6
doi: 10.1186/s13613-019-0616-6
pubmed: 31872319
pmcid: 6928167
Libert N, Bigaillon C, Chargari C et al (2015) Epstein-Barr virus reactivation in critically ill immunocompetent patients. Biomed J 38:70–76. https://doi.org/10.4103/2319-4170.132905
doi: 10.4103/2319-4170.132905
pubmed: 25179711
Imlay H, Limaye AP (2020) Current understanding of cytomegalovirus reactivation in critical illness. J Infect Dis 221:S94–S102. https://doi.org/10.1093/infdis/jiz638
doi: 10.1093/infdis/jiz638
pubmed: 32134490
pmcid: 7057786
Le Balc’h P, Pinceaux K, Pronier C et al (2020) Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients. Crit Care 24:530. https://doi.org/10.1186/s13054-020-03252-3
doi: 10.1186/s13054-020-03252-3
pubmed: 32859241
pmcid: 7453668
Moniz P, Brito S, Póvoa P (2021) SARS-CoV-2 and cytomegalovirus co-infections-a case series of critically ill patients. J Clin Med 10:2792. https://doi.org/10.3390/jcm10132792
doi: 10.3390/jcm10132792
pubmed: 34201947
pmcid: 8268027
Simonnet A, Engelmann I, Moreau A-S et al (2021) High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically ill patients with COVID-19. Infect Dis Now 51:296–299. https://doi.org/10.1016/j.idnow.2021.01.005
doi: 10.1016/j.idnow.2021.01.005
pubmed: 33495765
pmcid: 7816954
Franceschini E, Cozzi-Lepri A, Santoro A et al (2021) Herpes simplex virus re-activation in patients with SARS-CoV-2 pneumonia: a prospective, observational study. Microorganisms 9:1896. https://doi.org/10.3390/microorganisms9091896
doi: 10.3390/microorganisms9091896
pubmed: 34576791
pmcid: 8465957
Meyer A, Buetti N, Houhou-Fidouh N et al (2021) HSV-1 reactivation is associated with an increased risk of mortality and pneumonia in critically ill COVID-19 patients. Crit Care 25:417. https://doi.org/10.1186/s13054-021-03843-8
doi: 10.1186/s13054-021-03843-8
pubmed: 34872611
pmcid: 8647503
Al-Omari A, Aljamaan F, Alhazzani W et al (2016) Cytomegalovirus infection in immunocompetent critically ill adults: literature review. Ann Intensive Care 6:110. https://doi.org/10.1186/s13613-016-0207-8
doi: 10.1186/s13613-016-0207-8
pubmed: 27813024
pmcid: 5095093
Schildermans J, De Vlieger G (2020) Cytomegalovirus: a troll in the ICU? Overview of the literature and perspectives for the future. Front Med (Lausanne) 7:188. https://doi.org/10.3389/fmed.2020.00188
doi: 10.3389/fmed.2020.00188
Papazian L, Hraiech S, Lehingue S et al (2016) Cytomegalovirus reactivation in ICU patients. Intensive Care Med 42:28–37. https://doi.org/10.1007/s00134-015-4066-9
doi: 10.1007/s00134-015-4066-9
pubmed: 26424680
Chiche L, Forel J-M, Roch A et al (2009) Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med 37:1850–1857. https://doi.org/10.1097/CCM.0b013e31819ffea6
doi: 10.1097/CCM.0b013e31819ffea6
pubmed: 19384219
Barry SM, Johnson MA, Janossy G (2000) Cytopathology or immunopathology? The puzzle of cytomegalovirus pneumonitis revisited. Bone Marrow Transpl 26:591–597. https://doi.org/10.1038/sj.bmt.1702562
doi: 10.1038/sj.bmt.1702562
Papazian L, Thomas P, Bregeon F et al (1998) Open-lung biopsy in patients with acute respiratory distress syndrome. Anesthesiology 88:935–944. https://doi.org/10.1097/00000542-199804000-00013
doi: 10.1097/00000542-199804000-00013
pubmed: 9579502
Söderberg-Nauclér C (2021) Does reactivation of cytomegalovirus contribute to severe COVID-19 disease? Immun Ageing 18:12. https://doi.org/10.1186/s12979-021-00218-z
doi: 10.1186/s12979-021-00218-z
pubmed: 33712035
pmcid: 7952506
Papazian L, Jaber S, Hraiech S et al (2021) Preemptive ganciclovir for mechanically ventilated patients with cytomegalovirus reactivation. Ann Intensive Care 11:33. https://doi.org/10.1186/s13613-020-00793-2
doi: 10.1186/s13613-020-00793-2
pubmed: 33570708
pmcid: 7876264
Cowley NJ, Owen A, Shiels SC et al (2017) Safety and efficacy of antiviral therapy for prevention of cytomegalovirus reactivation in immunocompetent critically ill patients: a randomized clinical trial. JAMA Intern Med 177:774–783. https://doi.org/10.1001/jamainternmed.2017.0895
doi: 10.1001/jamainternmed.2017.0895
pubmed: 28437539
pmcid: 5818821
Limaye AP, Stapleton RD, Peng L et al (2017) Effect of ganciclovir on IL-6 levels among cytomegalovirus-seropositive adults with critical illness: a randomized clinical trial. JAMA 318:731–740. https://doi.org/10.1001/jama.2017.10569
doi: 10.1001/jama.2017.10569
pubmed: 28829877
pmcid: 5817487
Definition Task Force ARDS, Ranieri VM, Rubenfeld GD et al (2012) Acute respiratory distress syndrome: the Berlin Definition. JAMA 307:2526–2533. https://doi.org/10.1001/jama.2012.5669
doi: 10.1001/jama.2012.5669
World Health Organization (2021) COVID-19 clinical management: living guidance. World Health Organization, Geneva
Mussini C, Falcone M, Nozza S et al (2021) Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT). Clin Microbiol Infect 27:389–395. https://doi.org/10.1016/j.cmi.2020.12.011
doi: 10.1016/j.cmi.2020.12.011
pubmed: 33359375
pmcid: 7833273
Steinberg KP, Hudson LD, Goodman RB et al (2006) Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med 354:1671–1684. https://doi.org/10.1056/NEJMoa051693
doi: 10.1056/NEJMoa051693
pubmed: 16625008
Torres A, Niederman MS, Chastre J et al (2017) International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: Guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociación Latinoamericana del Tórax (ALAT). Eur Respir J 50:1700582. https://doi.org/10.1183/13993003.00582-2017
doi: 10.1183/13993003.00582-2017
pubmed: 28890434
Manian FA (2009) IDSA guidelines for the diagnosis and management of intravascular catheter-related bloodstream infection. Clin Infect Dis 49:1770–1771. https://doi.org/10.1086/648113
doi: 10.1086/648113
pubmed: 19891568
Koehler P, Bassetti M, Chakrabarti A et al (2021) Defining and managing COVID-19-associated pulmonary Aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infect Dis 21:e149–e162. https://doi.org/10.1016/S1473-3099(20)30847-1
doi: 10.1016/S1473-3099(20)30847-1
pubmed: 33333012
Fryer JF, Heath AB, Anderson R et al (2010) Collaborative study to evaluate the proposed 1st [first] WHO international standard for human cytomegalovirus (HCMV) for nucleic acid amplification (NAT)-based assays. World Health Organization, Geneva
Saade A, Moratelli G, Azoulay E, Darmon M (2021) Herpesvirus reactivation during severe COVID-19 and high rate of immune defect. Infect Dis Now 51:676–679. https://doi.org/10.1016/j.idnow.2021.07.005
doi: 10.1016/j.idnow.2021.07.005
pubmed: 34332165
pmcid: 8317452
Busani S, Bedini A, Biagioni E et al (2021) Two fatal cases of acute liver failure due to HSV-1 infection in COVID-19 patients following immunomodulatory therapies. Clin Infect Dis 73:e252–e255. https://doi.org/10.1093/cid/ciaa1246
doi: 10.1093/cid/ciaa1246
pubmed: 32840571
Osuchowski MF, Winkler MS, Skirecki T et al (2021) The COVID-19 puzzle: deciphering pathophysiology and phenotypes of a new disease entity. Lancet Respir Med 9:622–642. https://doi.org/10.1016/S2213-2600(21)00218-6
doi: 10.1016/S2213-2600(21)00218-6
pubmed: 33965003
pmcid: 8102044
Hosseini SF, Behnam-Roudsari S, Alavinia G et al (2021) Diagnostic and prognostic value of Sepsis-Induced coagulopathy and International Society on Thrombosis and Hemostasis scoring systems in COVID-19-associated disseminated intravascular coagulopathy. J Res Med Sci 26:102. https://doi.org/10.4103/jrms.JRMS_1295_20
doi: 10.4103/jrms.JRMS_1295_20
pubmed: 34899940
pmcid: 8607173
Lachance P, Chen J, Featherstone R, Sligl WI (2017) Association between cytomegalovirus reactivation and clinical outcomes in immunocompetent critically ill patients: a systematic review and meta-analysis. Open Forum Infect Dis 4:029. https://doi.org/10.1093/ofid/ofx029
doi: 10.1093/ofid/ofx029
Loftus TJ, Ungaro R, Dirain M et al (2021) Overlapping but disparate inflammatory and immunosuppressive responses to SARS-CoV-2 and bacterial sepsis: an immunological time course analysis. Front Immunol 12:792448. https://doi.org/10.3389/fimmu.2021.792448
doi: 10.3389/fimmu.2021.792448
pubmed: 34956225
pmcid: 8696010
Jaber S, Chanques G, Borry J et al (2005) Cytomegalovirus infection in critically ill patients: associated factors and consequences. Chest 127:233–241. https://doi.org/10.1378/chest.127.1.233
doi: 10.1378/chest.127.1.233
pubmed: 15653989
Rubio I, Osuchowski MF, Shankar-Hari M et al (2019) Current gaps in sepsis immunology: new opportunities for translational research. Lancet Infect Dis 19:e422–e436. https://doi.org/10.1016/S1473-3099(19)30567-5
doi: 10.1016/S1473-3099(19)30567-5
pubmed: 31630991
Venet F, Davin F, Guignant C et al (2010) Early assessment of leukocyte alterations at diagnosis of septic shock. Shock 34:358–363. https://doi.org/10.1097/SHK.0b013e3181dc0977
doi: 10.1097/SHK.0b013e3181dc0977
pubmed: 20220566
Clari MA, Aguilar G, Benet I et al (2013) Evaluation of cytomegalovirus (CMV)-specific T-cell immunity for the assessment of the risk of active CMV infection in non-immunosuppressed surgical and trauma intensive care unit patients. J Med Virol 85:1802–1810. https://doi.org/10.1002/jmv.23621
doi: 10.1002/jmv.23621
pubmed: 23868746
Kuo C-W, Wang S-Y, Tsai H-P et al (2021) Invasive pulmonary aspergillosis is associated with cytomegalovirus viremia in critically ill patients: a retrospective cohort study. J Microbiol Immunol Infect S1684–1182(21):00057–00058. https://doi.org/10.1016/j.jmii.2021.03.005
doi: 10.1016/j.jmii.2021.03.005